Background: Acute pericarditis generally follows a mild clinical course and is rarely fatal. Coronary vein involvement is rarely reported.
Case Summary: We report an autopsy case of cardiac tamponade from idiopathic myopericarditis due to coronary venous perforation under the triple antithrombotic therapy. A 69-year-old man was admitted to our hospital with abnormal findings on electrocardiography, bloody pericardial effusion, and mild elevation of troponin I. Oral anti-inflammatories were started and the patient followed a benign course. However, on hospital Day 5, he suddenly suffered cardiogenic shock with pulseless electric activity due to cardiac tamponade under the combination use of the dual antiplatelet drugs and an anticoagulant drug. He died despite intense medical treatment. Autopsy revealed cardiac tamponade caused by perforation in the coronary venous wall. To the best of our knowledge, this is the first description of fatal myopericarditis as a complication of coronary venous perforation.
Discussion: The aetiology and mechanism remain unknown; however, we should take care for this rare complication in patients with acute myopericarditis and bloody effusion under the triple antithrombotic therapy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8188861 | PMC |
| http://dx.doi.org/10.1093/ehjcr/ytab098 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Real-world antithrombotic strategies in patients with atrial fibrillation and recently developed acute coronary syndrome.
Int J Cardiol Cardiovasc Risk Prev
March 2025
Department of Cardiovascular Biology and Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Background: The antithrombotic strategy for patients with atrial fibrillation (AF) and coronary artery disease following percutaneous coronary intervention is shifting towards less intensive. Nevertheless, for patients with AF and acute coronary syndrome (ACS), an optimal antithrombotic strategy is yet to be established.
Methods And Results: We conducted a multi-center cohort study involving 146 Japanese centers that had prospectively registered 460 patients with AF and ACS followed for 2 years.
Efficacy and safety of low-dose acetylsalicylic acid for the prevention of thromboembolic events in individuals positive for antiphospholipid antibodies: A systematic review and meta-analysis.
Thromb Res
January 2025
Research Center on Thromboembolic Disorders and Antithrombotic Therapies, ASST Lariana, University of Insubria, Como, Italy. Electronic address:
Article Synopsis
- Anti-Phospholipid Antibodies (aPL) increase the risk of blood clots, and the effectiveness of antiplatelet drugs for preventing these clots in aPL carriers was evaluated through a systematic review of existing studies.
- The review included 1056 participants and found that low-dose acetylsalicylic acid (LDA) significantly reduced both arterial and venous thrombotic events compared to control groups without increasing major bleeding risks.
- However, the safety and benefit of LDA may vary depending on the specific aPL profile of the individuals, which remains uncertain.
Real-world Data of Antithrombotic Therapy in Neuroendovascular Therapy: Analysis of JR-NET 4.
Neurol Med Chir (Tokyo)
December 2024
Department of Neurosurgery, Hyogo Medical University.
Article Synopsis
- The study examines trends in antithrombotic therapy during neuroendovascular procedures in Japan, analyzing data from the JR-NET 4 registry covering 36,560 cases from 2015 to 2019.
- It found that the use of dual antiplatelet therapy (DAPT) significantly increased over the years, while monotherapy decreased; postprocedural anticoagulant therapy was notably discontinued.
- Additionally, complications related to ischemic events rose slightly, and the occurrence of severe adverse events was higher in patients receiving more extensive preprocedural therapy.
Antithrombotic therapy in patients with atrial fibrillation after percutaneous coronary intervention.
Expert Rev Cardiovasc Ther
September 2024
Cardiovascular Research Unit, Division of Clinical Medicine, School of Medicine and Population Health, University of Sheffield, Sheffield, UK.
Introduction: Patients who undergo percutaneous coronary intervention (PCI) with stenting usually require a period of dual antiplatelet therapy (DAPT) but, when an indication for long-term oral anticoagulation (OAC) such as atrial fibrillation (AF) coexists, triple antithrombotic therapy (TAT) with DAPT and OAC causes concern for excessive bleeding. Achieving the right balance between bleeding and adequate protection from ischemic events remains an issue of debate and subject to ongoing investigation of various antithrombotic regimens and durations.
Areas Covered: This review describes the landmark clinical trials comparing TAT to a period of dual antithrombotic therapy (DAT) and subsequent meta-analyses.
Patients with atrial fibrillation (AF) often develop acute coronary syndrome and undergo percutaneous coronary intervention (PCI), and vice versa. Acute coronary syndrome and PCI mandate the use of dual antiplatelet therapy, while oral anticoagulation is recommended in patients with AF to mitigate thromboembolic risks. Clinical evidence concerning antithrombotic treatment in patients with AF and PCI has been accumulated, but when combined, the therapeutic strategy becomes complex.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!